Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Many core pharmacology/indication statements align with the label, but several dosing, safety, and formulation/brand-name assertions are either partially inaccurate or not supported by the provided label excerpts. Off-label use, steroid/immune-suppression comparisons, and specific side-effect severity/timing claims exceed what is supported in the supplied label text.
Category Scores
Accurate Statements
Prolensa is not the same medication as bromfenac.
Not evaluable from the provided label excerpts; however, this statement is not contradicted by the provided information.
The active ingredient in Prolensa is bromfenac.
Not supported by the provided FDA label excerpts (brand equivalence not provided). No contradiction in provided excerpts.
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID).
12.1 Mechanism of Action: bromfenac is an NSAID.
Bromfenac is used to treat pain and inflammation associated with ocular surgery.
1 Indications and Usage: postoperative inflammation and reduction of ocular pain in cataract surgery patients.
Bromfenac works by inhibiting cyclooxygenase (COX) enzymes.
12.1: blocks prostaglandin synthesis by inhibiting COX 1 and 2.
COX enzymes are involved in the synthesis of prostaglandins.
12.1: prostaglandin synthesis blocked via COX 1 and 2 inhibition (supports the relationship).
Bromfenac ophthalmic solutions are approved by regulatory agencies like the U.S. Food and Drug Administration (FDA) for specific medical uses.
Supported generally by the presence of FDA-approved label excerpts; no contrary label excerpt provided.
The bromfenac dosage continues for 14 days postoperatively.
2.1: continued through the first 14 days of the postoperative period.
Commonly reported adverse reactions include eye pain and vision blurred.
6.1: eye pain and vision blurred are among most commonly reported reactions.
All topical NSAIDs, including bromfenac, may slow or delay healing.
5.2 Slow or Delayed Healing: topical NSAIDs including bromfenac may slow/delay healing.
There is potential cross-sensitivity to other NSAIDs, including bromfenac.
5.3 Potential for Cross-Sensitivity.
Use may result in keratitis and corneal reactions; continued use may result in epithelial breakdown and corneal thinning/ulceration/perforation in susceptible patients.
5.5 Keratitis and Corneal Reactions.
There are reports of ocular NSAIDs causing increased bleeding of ocular tissues in conjunction with ocular surgery; use caution in patients with known bleeding tendencies.
5.4 Increased Bleeding Time.
Do not touch dropper tip to the eye, eyelids, or any surface; replace bottle cap after using.
5.6 Risk of Contamination.
Bromfenac ophthalmic solution should not be instilled while wearing contact lenses; remove lenses prior and reinsert after 10 minutes.
5.7 Contact Lens Wear.
Clinical trials evaluated bromfenac 0.07% QD starting 1 day prior to cataract surgery, through surgery day, and for 14 days after surgery, and showed superiority to vehicle.
14.1 Clinical Studies.
Unsupported Statements
Bromfenac is available under various brand names, including Prolensa and Bromday.
Brand-name equivalence is not addressed in the provided label excerpts.
Prolensa and Bromday both contain bromfenac as their active ingredient.
Not supported by the provided label excerpts.
Common side effects of bromfenac include eye irritation, blurred vision, and decreased visual acuity.
The label excerpt lists specific commonly reported reactions: anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and vision blurred; 'eye irritation' and 'decreased visual acuity' are not explicitly stated.
Serious side effects of bromfenac can include corneal thinning or melting, especially with prolonged use.
The label mentions corneal thinning/erosion/ulceration/perforation and that events may be sight threatening; 'melting' is not explicitly used in the provided excerpt.
Patients with known hypersensitivity to NSAIDs should use these medications with caution.
The label supports caution for individuals with previously exhibited sensitivities to related drugs (cross-sensitivity), but does not specifically frame it as 'known hypersensitivity to NSAIDs' in that wording.
Steroid eye drops such as prednisolone or loteprednol are commonly prescribed to manage inflammation after eye surgery.
Not supported; label excerpt only states topical corticosteroids slow/delay healing and concomitant use may increase healing problems; no specific steroid examples or 'commonly prescribed' claim.
Steroid eye drops suppress the immune response.
Not supported by the provided label excerpts.
NSAIDs like bromfenac are sometimes used off-label for other inflammatory eye conditions.
Not addressed in the provided label excerpts.
NSAID eye drops can cause delayed wound healing.
The label says 'slow or delay healing' (ocular healing context), but 'delayed wound healing' is not verbatim and is not explicitly framed as wound healing.
NSAID eye drops can cause infection.
Infection is not mentioned in the provided warnings/adverse-reaction excerpts.
NSAID eye drops can cause corneal complications such as ulceration, perforation, and melting.
Ulceration and perforation are supported; 'melting' is not explicitly stated in the provided excerpt.
A common dosage for bromfenac ophthalmic solution is one drop in the affected eye twice daily.
The provided label excerpt specifies one drop once daily (QD), not twice daily.
The bromfenac dosage starts 24 hours after surgery.
The label says start 1 day prior to surgery (and continue through surgery day).
The bromfenac dosage starts 24 hours after surgery.
Label dosing begins 1 day prior to cataract surgery, not 24 hours after surgery.
Steroid eye drops such as prednisolone or loteprednol are commonly prescribed to manage inflammation after eye surgery.
Specific drugs and 'commonly prescribed' are not supported by the provided excerpts.
Contradictions
High
AI Statement
A common dosage for bromfenac ophthalmic solution is one drop in the affected eye twice daily.
Label Reference
2.1 Recommended Dosage: Apply one drop ... once daily (QD).
High
AI Statement
The bromfenac dosage starts 24 hours after surgery.
Label Reference
2.1 Recommended Dosage: beginning 1 day prior to cataract surgery ...
Important Omissions
Label-supported instruction to apply one drop once daily beginning 1 day prior to surgery, continued on the day of surgery, and through the first 14 postoperative days (explicit once-daily regimen and preoperative start).
Importance:
Moderate
Use with other topical ophthalmic medications should be at least 5 minutes apart.
Importance:
Low
Sulfite content warning (sodium sulfite) with potential allergic-type reactions in susceptible people.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Contradicted dosing frequency and timing (twice daily; starting 24 hours after surgery) could materially misalign with the label regimen. Other safety statements are partially supported but include unsupported claims (e.g., infection; steroid immune suppression; 'melting').
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Dosing assertions conflict with the label (twice daily and post-surgery start), and some safety/brand/off-label/side-effect phrasing is not supported by the provided label excerpts.
Suggested Improvement
Replace twice-daily and '24 hours after surgery' claims with the label’s once-daily regimen starting 1 day prior to cataract surgery through postoperative day 14; restrict side-effect and safety claims to those explicitly present in the provided label text; remove or qualify unsupported brand-name equivalence, off-label use, infection, and 'melting' terminology.